Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027

KT-621 BREADTH Phase 2b trial in asthma on track to initiate in 1Q26

Read more at globenewswire.com